Lucid Diagnostics (NASDAQ:LUCD) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Lucid Diagnostics (NASDAQ:LUCD) from a sell rating to a hold rating in a research note issued to investors on Sunday morning.

A number of other equities research analysts have also issued reports on LUCD. Needham & Company LLC reiterated a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research note on Wednesday, August 13th. Ascendiant Capital Markets raised their price objective on Lucid Diagnostics from $7.50 to $7.75 and gave the company a “buy” rating in a research note on Friday, June 6th. Finally, BTIG Research raised their price objective on Lucid Diagnostics from $2.00 to $2.50 and gave the company a “buy” rating in a research note on Friday, September 5th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $3.65.

Lucid Diagnostics Stock Performance

LUCD stock opened at $1.03 on Friday. Lucid Diagnostics has a 1 year low of $0.75 and a 1 year high of $1.80. The firm has a market cap of $137.48 million, a P/E ratio of -0.87 and a beta of 1.24. The stock has a 50-day simple moving average of $1.09 and a 200-day simple moving average of $1.23.

Insider Activity at Lucid Diagnostics

In other news, Director Dennis Matheis bought 100,000 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was bought at an average price of $1.02 per share, for a total transaction of $102,000.00. Following the transaction, the director owned 665,443 shares in the company, valued at $678,751.86. The trade was a 17.69% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 6.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in LUCD. Alyeska Investment Group L.P. acquired a new position in shares of Lucid Diagnostics in the 1st quarter worth approximately $2,813,000. Geode Capital Management LLC grew its position in shares of Lucid Diagnostics by 420.3% in the 2nd quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock worth $1,814,000 after acquiring an additional 1,274,194 shares in the last quarter. Ghisallo Capital Management LLC acquired a new position in shares of Lucid Diagnostics in the 1st quarter worth approximately $629,000. XML Financial LLC acquired a new position in shares of Lucid Diagnostics in the 1st quarter worth approximately $266,000. Finally, Citadel Advisors LLC acquired a new position in shares of Lucid Diagnostics in the 4th quarter worth approximately $98,000. Institutional investors and hedge funds own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.